NCT03895762View on ClinicalTrials.gov

Observational Study of Efficacy, Safety and Tolerability of Fentanyl in Korean Cancer Patients

CompletedOBSERVATIONAL
Enrollment

143

Participants

Timeline

Start Date

July 4, 2017

Primary Completion Date

June 28, 2019

Study Completion Date

June 28, 2019

Conditions
Breakthrough Cancer Pain
Interventions
DRUG

Abstral Oral Disintegrating Tablet (ODT)

Opioid(Fentanyl)

Trial Locations (1)

06351

Samsung Medical Center, Seoul

All Listed Sponsors
lead

A.Menarini Asia-Pacific Holdings Pte Ltd

INDUSTRY

NCT03895762 - Observational Study of Efficacy, Safety and Tolerability of Fentanyl in Korean Cancer Patients | Biotech Hunter | Biotech Hunter